ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

This study has been completed.

Sponsored by: National Cancer Institute (NCI)
Memorial Sloan-Kettering Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of 6- hydroxymethylacylfulvene in treating patients with metastatic kidney cancer.

Condition Treatment or Intervention Phase
Stage IV Renal Cell Cancer
recurrent renal cell cancer
 Drug: -hydroxymethylacylfulvene
Phase II

MedlinePlus related topics:  Cancer;   Cancer Alternative Therapy;   Kidney Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of 6-Hydroxymethylacylfulvene for Advanced Renal Cell Carcinoma

Further Study Details: 

Study start: June 1998

OBJECTIVES: I. Evaluate the efficacy of 6-hydroxymethylacylfulvene (HMAF) in patients with metastatic renal cell carcinoma.

II. Investigate the safety of HMAF given to this patient population.

PROTOCOL OUTLINE: Patients receive 6-hydroxymethylacylfulvene intravenously for 5 minutes every day for 5 consecutive days. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed after every 2 treatment courses.

PROJECTED ACCRUAL: Approximately 12-37 patients will be accrued for this study within 6-19 months.

Eligibility

Ages Eligible for Study:  18 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

--Prior/Concurrent Therapy--

--Patient Characteristics--


Location Information


New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States

Study chairs or principal investigators

William Berg,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000066388; MSKCC-98009; NCI-T97-0119; MSKCC-98007
Record last reviewed:  August 2004
Record first received:  November 1, 1999
ClinicalTrials.gov Identifier:  NCT00003390
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-10-20
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act